

<https://helda.helsinki.fi>

Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum

PLSD Collaborators

2021-01-15

PLSD Collaborators , Dominguez-Valentin , M , Sampson , J R , Møller , P & Seppälä , T T
2021 , ' Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of
the Lynch syndrome tumor spectrum ' , International Journal of Cancer , vol. 148 , no. 2 , pp.
512-513 . <https://doi.org/10.1002/ijc.33214>

<http://hdl.handle.net/10138/332570>

<https://doi.org/10.1002/ijc.33214>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch Syndrome tumor spectrum

Dear Editor,

Lynch Syndrome (LS) is the most common hereditary cancer syndrome. It results from heterozygous pathogenic germline variants in the mismatch repair (MMR) genes that are carried by over 1 in 200 individuals. Pathogenic variants in each of the MMR genes, *path_MLH1*, *path_MSH2*, *path_MSH6*, and *path_PMS2*, result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas and upper urinary tract ¹. These cancers, but not sarcomas, are commonly cited as LS spectrum cancers. Sarcomas include osteosarcomas (OS) that have a worldwide incidence of 4.3 per million in males and 3.4 per million females per year ², and soft tissue sarcomas (STS) that are a heterogeneous group of cancers of mesenchymal origin with a population incidence of 3.5 per 100,000 people per year in the US ³. In the most recent study from the Prospective Lynch Syndrome Database (PLSD) we reported 14 cases of sarcoma among 1808 prospectively observed tumors in 6350 carriers of *path_MMR* variants with 51,646 follow up years (FUY) ¹.

The PLSD is an international multi-center prospective observational study without a control group, in which we record cancers diagnosed in genetically confirmed carriers of class 4 and 5 *path_MMR* variants undergoing long-term surveillance. Data on previous cancers are collected at inclusion.

In the PLSD, the mean age at prospective diagnosis of OS (n=10) was 63 years (range, 32-74) and of STS (n=4) 62 years (range, 57-71). More than half of sarcomas (57%, 8/14) occurred in *path_MSH2* carriers even though they comprised only 40% of PLSD patients, 21% were in *path_MLH1* (3/14), 14% in *path_PMS2* (2/14) and 7% (1/14) in *path_MSH6* carriers. The type of

path_MMR variants identified in OS and STS patients were mainly predicted to cause missense changes (57%, 8/14), followed by deletions (4/14) and predicted splicing changes (2/14). Eight of 14 patients (57%) were male.

Comparing the prospectively observed incidence of OS in the PLSD (21 per 100,000 FUY) to the worldwide general population incidence reported by Mirabello et al. showed a 50–63-fold relative incidence in LS ². This is particularly striking as OS is primarily a cancer of childhood and adolescence, while in the PLSD, prospective observation is limited to ages 25–80 years ¹. Cumulative incidence at 75 years (95% confidence interval) was 0.73% (0 – 1.56), 4.24% (0.54–7.93), 0 and 1.57% (0–4.63) in *path_MLH1*, *path_MSH2*, *path_MSH6* and *path_PMS2* carriers, respectively, which for *path_MSH2* carriers was significantly higher than the 0.1% population cumulative incidence at 75 years ($p < 0.05$) ^{3,4}. Lifetime risk of OS in *path_MSH2* carriers based on this comparison would be 42.4-fold (5.4 to 79.3) that of the general population.

In addition to the 14 prospectively observed sarcomas in the PLSD, 16 further patients had been affected by sarcoma before or at their inclusion: 5 with OS and 11 with STS, with mean ages at diagnosis of 48.2 (range, 4–64) and 35.1 (range, 24–54) years, respectively. Again, *path_MSH2* carriers were the most frequently affected (50%, 8/16), followed by *path_MLH1* carriers (38%, 6/16). Regarding the type of *path_MMR* variants identified in these patients, predicted missense changes were most common (7/16), followed by splicing (5/16) and deletion variants (4/16). Regarding gender, equal numbers of females (8) and males (8) were affected.

There is a paucity of studies linking OS and LS, even though MMR deficiency (dMMR) is seen very frequently in OS. In one previous study, loss of expression of MSH2/MSH6 was observed in 81% (54/67) of OS and was associated with better prognosis ⁵. By contrast, in another

retrospective study of 304 sarcomas that included only one case of OS, dMMR was confirmed in only 2.3% (7/304), and LS was diagnosed in one of these (14%) ⁶.

A more recent study found that 6% (45/785) of STS had a microsatellite instability high (MSI-H) or intermediate (MSI-I) signature, and this was concordant with dMMR evaluated by immunohistochemistry. Two of the 45 cases (4.4%) had LS ⁷. Most recently, *MSH2* was reported as one of a small number of genes that showed a significantly higher burden of pathogenic or likely pathogenic variants in European OS patients compared to controls (0.4%, 3 of 732 patients) ⁸.

We conclude that the incidence of OS in LS patients is significantly increased compared to the general population. We suggest that osteosarcoma is part of the LS spectrum in adults and seems to be associated particularly with the *path_MSH2* genotype. The association of STS with *path_MMR* variants is currently less clear, although there are case reports on young LS carriers with soft tissue sarcomas ^{9,10}.

List of abbreviations

dMMR: MMR deficiency

FUY: Follow up years

LS: Lynch syndrome

MMR: Mismatch repair

MSI-H: microsatellite instability high

MSI-I: microsatellite instability intermediate

OS: Osteosarcoma

path_MLH1: Pathogenic (disease-causing) variants of the *MLH1* gene

path_MSH2: Pathogenic (disease-causing) variants of the *MSH2* gene

path_MSH6: Pathogenic (disease-causing) variants of the *MSH6* gene

path_PMS2: Pathogenic (disease-causing) variants of the *PMS2* gene

PLSD: Prospective Lynch Syndrome Database

SFT: Soft tissue sarcoma

Acknowledgments

The PLSD would not have been possible without its many contributors and without initial support from the core members of The European Hereditary Tumour Group (former Mallorca group) contributing all their follow-up data for the first PLSD version.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval of the study

The study adhered to the principles set out in the Declaration of Helsinki. It was approved by the Oslo University Hospital ethical committee ref. S-02030 and its data governance rules by the Norwegian Data Inspectorate ref. 2001/2988-2. Genetic testing was performed with informed consent according to local and national requirements and all reporting centers exported only de-identified data to PLSD.

Data accessibility

The cancer risk algorithm is available at the PLSD website (www.plsd.eu) that is based upon the results presented in this report and enables interactive calculation of remaining lifetime risks for cancer in any LS patient by giving their age, gender, and gene variant.

Full list of authors and affiliations

Mev Dominguez-Valentin PhD¹, Julian R. Sampson DM², Pål Møller MD¹ and Toni T. Seppälä MD³ on behalf of the PLSD collaborators.

1. Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Oslo, Norway
2. Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, Cardiff, UK
3. Department of Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Corresponding authors:

Mev Dominguez-Valentin, Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Oslo, Norway, mail: mev.dominguez.valentin@rr-research.no

Toni T. Seppälä, Department of Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, mail: toni.seppala@fimnet.fi

PLSD collaborators

John-Paul Plazzer, BE
Sigve Nakken, PhD
Christoph Engel, MD
Stefan Aretz, MD
Mark A. Jenkins, PhD
Lone Sunde, MD, PhD
Inge Bernstein, MD, PhD
Gabriel Capella, MD
Francesc Balaguer, MD
Huw Thomas, PhD, FRCP
D. Gareth Evans, MD FRCP
John Burn, MD, FMedSci
Marc Greenblatt, MD
Eivind Hovig, PhD
Maartje Nielsen, MD, PhD
Wouter H. de Vos tot Nederveen Cappel, MD
Rolf H. Sijmons, MD
Lucio Bertario, MD
Maria Grazia Tibiletti, MD
Giulia Martina Cavestro, MD
Annika Lindblom, MD
Adriana Della Valle, MD
Francisco Lopez-Köstner, MD, PhD
Nathan Gluck, MD, PhD
Lior H. Katz, MD
Karl Heinimann, MD, PhD
Carlos A. Vaccaro, MD
Reinhard Büttner, MD
Heike Görgens, MD
Elke Holinski-Feder, MD
Monika Morak, PhD
Stefanie Holzapfel, MD

Robert Hüneburg, MD
Magnus von Knebel Doeberitz, MD
Markus Loeffler, MD
Nils Rahner, MD
Jürgen Weitz
Verena Steinke-Lange, MD
Sanne W. ten Broeke, PhD
Wolff Schmiegel, MD
Deepak Vangala, MD
Kirsi Pylvänäinen, MD
Laura Renkonen-Sinisalo, MD
John L. Hopper, PhD
Aung Ko Win, PhD
Robert W. Haile, PhD
Noralane M. Lindor, MD
Steven Gallinger, MD, PhD
Loïc Le Marchand, PhD
Polly A. Newcomb, PhD
Jane C. Figueiredo, PhD
Stephen N. Thibodeau, PhD
Lars Henrik Jensen, MD, PhD
Majbritt Busk Madsen, PhD
Lone Krøldrup, MD
Mef Nilbert, MD, PhD
Leticia Moreira, MD
Ariadna Sánchez, MD
Miquel Serra-Burriel, PhD
Marta Pineda, PhD
Matilde Navarro, MD
Joan Brunet Vidal
Ignacio Blanco, MD
Kate Green, MD
Fiona Lalloo, MD, FRCP
Emma J. Crosbie, PhD, MRCOG
James Hill, MD
Oliver G. Denton, BSc
Einar Andreas Rødland, PhD
Hans Vasen, MD
Miriam Mints, MD
Floencia Neffa, MD
Patricia Esperon, PhD
Karin Alvarez, PhD
Revital Kariv, MD
Guy Rosner, MD
Tamara Alejandra Pinero, PhD
María Laura Gonzalez, MD

Pablo Kalfayan, MD
Douglas Tjandra, MD
Ingrid M. Winship, MD
Finlay Macrae, MD
Gabriela Möslein, MD
Jukka-Pekka Mecklin, MD

Keywords: Lynch syndrome, sarcoma, *MSH2*.

References

1. Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med*. 2019.
2. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. *Int J Cancer*. 2009;125(1):229-234.
3. Surveillance E, and End Results (SEER) Program (www.seer.cancer.gov) 2020.
4. Norway. CRo. *Cancer in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway*. 2018.
5. Jentzsch T, Robl B, Husmann M, Bode-Lesniewska B, Fuchs B. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma. *Anticancer Res*. 2014;34(12):6961-6972.
6. Doyle LA, Nowak JA, Nathenson MJ, et al. Characteristics of mismatch repair deficiency in sarcomas. *Mod Pathol*. 2019;32(7):977-987.
7. Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J Clin Oncol*. 2019;37(4):286-295.
8. Mirabello L, Zhu B, Koster R, et al. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. *JAMA Oncol*. 2020.
9. Bjorkman P, Kantonen I, Blomqvist C, Venermo M, Alback A. En bloc resection of visceral aorta and right kidney due to aortic sarcoma using temporary extracorporeal bypass grafting. *J Vasc Surg Cases Innov Tech*. 2019;5(4):589-592.
10. Tlemsani C, Leroy K, Gimenez-Roqueplo AP, et al. Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. *J Med Genet*. 2020;57(2):104-108.